Addendum

Dabrafenib/trametinib - Addendum to Commissions A15-39 and A15-40

Status
Status: Commission completed
Project no.
A16-05
Last updated

Report documents

  1. Addendum

    Dabrafenib/trametinib - Addendum to Commissions A15-39 and A15-40

    published on
    Document type
    PDF document, 95 kB, EN, not accessible

Press releases

Dabrafenib/trametinib: considerable added benefit for men with advanced melanoma

Study data subsequently submitted allow quantification / still major added benefit for women

Additional information

Federal Joint Committee (G-BA)

2016-03-17 A G-BA decision was published on trametinib.

G-BA documents on this decision

2016-03-17 A G-BA decision was published on dabrafenib.

G-BA documents on this decision

Project details

Project no.
A16-05
Commission
Commission awarded on 09.02.2016 by the Federal Joint Committee (GBA).
Report type
Addendum
Status
Commission completed
Department/Division
Drug Assessment
Topic
Skin and hair
Note

If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently on the extent of the added benefit, thus completing the early benefit assessment: decides-dabrafenib / decides-trametinib

Connected Projects

  1. Dossier assessment

    Dabrafenib (new therapeutic indication) - Benefit assessment according to §35a Social Code Book V

    Project no.
    A15-39
    Last updated

    Status: Commission completed

  2. Dossier assessment

    Trametinib - Benefit assessment according to §35a Social Code Book V (dossier assessment)

    Project no.
    A15-40
    Last updated

    Status: Commission completed

Contact

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form